RT Journal Article
T1 Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer.
A1 Fernández Montes, A
A1 Élez, E
A1 Vivancos, A
A1 Martínez, N
A1 González, P
A1 Covela, M
A1 de la Cámara, J
A1 Cousillas, A
A1 Méndez, J C
A1 Graña, B
A1 Aranda, E
K1 Circulating tumor DNA
K1 EGFR inhibitors
K1 Liquid biopsy
K1 Metastatic colorectal cancer
K1 RAS mutant
AB Some patients with histologically confirmed primary mCRC and mutated RAS reported undetectable RAS mutant clones in plasma after receiving anti-VEGF treatment. The aim was to prospectively assess it with its potential therapeutic implications. RAS mutant genes in solid biopsy (before first-line treatment: FOLFOX/CAPOX + bevacizumab) were compared in liquid biopsy (before second-line treatment: panitumumab + FOLFIRI), using Idylla™ system. Discordant results between solid/liquid biopsies were assessed by the next-generation sequencing (NGS) test (solid/liquid biopsies). Twenty-three patients were assessed (seven had RAS mutant discrepancies between solid/liquid biopsies). The NGS test confirmed that 3/23 (13%) patients had undetectable RAS mutant clones in liquid biopsy and 3/23 (13%) presented discrepancies in solid biopsy (Idylla™ system vs. NGS test). Thirteen percentage of patients had undetectable RAS mutant clones in liquid biopsy after first-line treatment. However, some discrepancies between solid and liquid biopsies have been observed. These results suggest a need to improve accuracy of RAS analyses, especially in solid biopsies.
YR 2022
FD 2022-01-07
LK http://hdl.handle.net/10668/21019
UL http://hdl.handle.net/10668/21019
LA en
DS RISalud
RD Apr 7, 2025